Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial.

Elewski, B E; Baker, C S; Crowley, J J; Poulin, Y; Okun, M M; Calimlim, B; Geng, Z; Reyes Servin, O; Rich, P A

Adalimumab for nail psoriasis: efficacy and safety over 52 weeks from a phase-3, randomized, placebo-controlled trial.

Elewski, B E; Baker, C S; Crowley, J J; Poulin, Y; Okun, M M; Calimlim, B; Geng, Z; Reyes Servin, O; Rich, P A.

Affiliation

Elewski BE; School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Baker CS; Skin & Cancer Foundation Inc and Probity Medical Research, Carlton, Vic., Australia.
Crowley JJ; Bakersfield Dermatology, Bakersfield, CA, USA.
Poulin Y; Centre de Recherche Dermatologique du Québec Métropolitain, Québec City, QC, Canada.
Okun MM; Fort Healthcare, Fort Atkinson, WI, USA.
Calimlim B; AbbVie Inc, North Chicago, IL, USA.
Geng Z; AbbVie Inc, North Chicago, IL, USA.
Reyes Servin O; AbbVie Inc, North Chicago, IL, USA.
Rich PA; Oregon Health and Science University Hospital, Portland, OR, USA.

J Eur Acad Dermatol Venereol ; 33(11): 2168-2178, 2019 Nov.

Article in En | MEDLINE | ID: mdl-31304993

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Psoriasis / Adalimumab / Nail Diseases Type of study: Clinical_trials / Prognostic_studies Limits: Adult / Female / Humans / Male / Middle aged Language: En Journal: J Eur Acad Dermatol Venereol Journal subject: DERMATOLOGIA / DOENCAS SEXUALMENTE TRANSMISSIVEIS Year: 2019 Document type: Article Affiliation country: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google